Andrology Research Unit, Manchester Academic Health Science Centre, Manchester Royal Infirmary, The University of Manchester, Manchester, United Kingdom.
J Clin Endocrinol Metab. 2011 Feb;96(2):454-8. doi: 10.1210/jc.2010-1167. Epub 2010 Nov 17.
Short-term testosterone (T) treatment in frail elderly men improves muscle mass and strength. It is unclear whether these effects can be maintained post treatment.
To assess the durability of androgen effects in frail men.
Single center, randomized, double-blind, placebo-controlled trial to investigate the effects of 6 months T (25-75 mg daily) on muscle strength, body composition, physical function, and quality of life (QoL). Participants were assessed at the end of treatment (6 months) and 6 months after treatment cessation (12 months).
274 intermediate-frail and frail elderly men aged 65-90 years with low T levels.
Mean T increased from 11.1 (3.1) nmol/liter at baseline to 18.4 (3.5) nmol/liter at 6 months, then declined to 10.5 (3.7) nmol/L at 12 months, in the T-treated group. Isometric knee extension peak torque increased in the T-treated group compared with placebo to give an adjusted mean difference (95% CI) between groups of 8.1 (-0.2 to 16.5) Nm at 6 months. Lean mass increased in the T-treated group giving a difference between groups of 1.2 (0.8 to 1.7) kg at 6 months. Somatic and sexual symptoms improved during treatment. None of these differences between groups remained at 12 months. Prostate specific antigen (PSA) levels and haematocrit increased slightly during treatment but returned to baseline by 12 months.
The effects of 6-month T treatment on muscle strength, lean mass, and QoL in frail men are not maintained at 6 months post treatment.
短期睾丸素（T）治疗虚弱的老年男性可以增加肌肉质量和力量。目前尚不清楚这些效果在治疗后是否能够维持。
评估雄激素对虚弱男性的持久作用。
这是一项为期 6 个月的单中心、随机、双盲、安慰剂对照试验，旨在研究 6 个月 T（每天 25-75 毫克）治疗对肌肉力量、身体成分、身体功能和生活质量（QoL）的影响。参与者在治疗结束时（6 个月）和治疗停止后 6 个月（12 个月）进行评估。
274 名年龄在 65-90 岁、睾丸激素水平较低、身体介于中度虚弱和虚弱之间的男性。
T 治疗组的平均 T 水平从基线时的 11.1（3.1）nmol/L 升高至 6 个月时的 18.4（3.5）nmol/L，然后在 12 个月时下降至 10.5（3.7）nmol/L。与安慰剂相比，T 治疗组的等长膝关节伸肌峰值扭矩增加，组间调整平均差异（95%置信区间）为 6 个月时 8.1（-0.2 至 16.5）Nm。T 治疗组的瘦体重增加，组间差异为 6 个月时 1.2（0.8 至 1.7）kg。治疗期间躯体和性功能症状改善。这些组间差异在 12 个月时均未持续存在。前列腺特异性抗原（PSA）水平和红细胞压积在治疗期间略有升高，但在 12 个月时恢复到基线。
6 个月 T 治疗对虚弱男性肌肉力量、瘦体重和生活质量的影响在治疗结束后 6 个月时无法维持。
